Rheumatologists treating HIV patients in 2017 must think through many important factors as this population ages. As we continue to learn, rheumatologists must consider important drug–drug interactions, relatively uncommon rheumatological presentations of HIV, as well as specific diagnostic challenges. Working closely with infectious disease specialists is the best way to achieve optimum care for this…
On Feb. 16, ACR leaders, insurers, pharmaceutical representatives, patients, patient advocacy representatives and more met in Scottsdale, Ariz. They came together for the first annual RISE Summit, aimed at setting strategic priorities and goals for the Rheumatology Informatics System for Effectiveness (RISE) Registry, the qualified clinical data registry developed by the ACR. The Rise of…
Thousands of attendees travel to the ACR/ARHP Annual Meeting from outside the U.S. to learn, network and exchange ideas. From Nov. 3–8 in San Diego, speakers from more than 30 different countries are scheduled to participate. The ACR is taking action to maintain diverse attendance in a challenging climate for international travel. New traveler vetting and…
In response to the required changes in reimbursement from fee for service to value-based payment under the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015, the ACR is exploring development of a rheumatology-specific alternative payment model (APM) for rheumatologists and practices, which would provide an additional option for payment other than the Merit-Based Incentive…
On May 25, with Gov. Greg Abbott’s signing of Senate Bill 680, Texas became the fourth state this year to increase protection for patients subject to insurers’ step therapy protocols. The State of Texas Association of Rheumatologists (STAR) joined with 35 other professional societies and patient advocacy organizations in urging passage of S.B. 680. The…
Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…
Are you a physician with a patient who no longer requires medical treatment? Do you have a patient you believe would be better served by another physician, specialist or practice due to a developing condition? Do you want to terminate a patient relationship because it is costing more than it is worth to your practice?…
The presence of synovial monosodium urate monohydrate (MSU) crystals is the gold standard for diagnosing gout. But a new study, funded in part by the ACR and led by rheumatologists, including Alexis Ogdie, MD, MSCE, evaluated the effectiveness of ultrasound in diagnosing it. The study found that ultrasound can be useful in discriminating gout from non-gout….
New methods of gene sequencing have resulted in improved identification of mutations in patients and increased availability of genetic testing in rare diseases. Despite these exciting advances, a majority of patients lack identifiable mutations and the underlying disease etiology remains an enigma. Somatic mosaicism (SM) may be an explanation for some of these clinically challenging…
Rheumatologists now have another treatment option to offer their patients with one of, if not the most, difficult autoimmune diseases to treat. New data add to the growing evidence of the safety and benefit of stem cell transplantation for patients with systemic sclerosis with internal organ involvement. New results of the Scleroderma: Cyclophosphamide or Transplantation…